• Bobcat339: Unlocking TET-Driven Epigenetic Control in Diseas

  2026-05-14

  Discover how Bobcat339, a cytosine structure-based TET enzyme inhibitor, enables deeper exploration of DNA methylation regulation in complex disease models. This article uniquely connects mechanistic insight to practical assay strategy, advancing epigenetics research beyond protocol basics.

• Imeglimin Enhances Mitochondrial Function in CTS SSCT Cells

  2026-05-14

  This study demonstrates that Imeglimin significantly improves mitochondrial function and reduces apoptosis in subsynovial connective tissue (SSCT)-derived cells from patients with idiopathic carpal tunnel syndrome. By utilizing multiparametric assays, the authors provide new evidence supporting mitochondrial dysfunction as a therapeutic target in CTS and establish quantitative frameworks for future research.

• Methyl-β-cyclodextrin: Technical Guidance for Membrane Studi

  2026-05-13

  Methyl-β-cyclodextrin (SKU C6939) is a high-purity reagent designed for selective extraction of cholesterol and other lipids from cellular membranes, enabling precise modulation of membrane fluidity and organization. It is best used in cell-based and biochemical workflows investigating membrane dynamics, lipid raft structure, and cholesterol-dependent signaling. This product is not intended for diagnostic or clinical applications and requires adherence to specific handling and storage protocols to maintain efficacy.

• β-Hydroxybutyrylation of ARG1 Reprograms Arginine Metabolism

  2026-05-13

  This study uncovers how abnormal β-hydroxybutyrylation of arginase-1 (ARG1) drives arginine metabolic reprogramming in colorectal cancer (CRC). By elucidating a novel post-translational modification axis involving ARG1-Kbhb, P300, and SLC3A2, the research clarifies mechanisms linking metabolic shifts to tumor progression and suggests new therapeutic approaches targeting ARG1's enzymatic and non-enzymatic functions.

• Glucocorticoids Promote Steroid Resistance in T-ALL via IL-7

  2026-05-12

  This study uncovers a paradoxical mechanism by which glucocorticoids (GCs), essential for T cell acute lymphoblastic leukemia (T-ALL) therapy, can induce their own resistance through upregulation of the IL-7 receptor and downstream BCL-2 signaling. These findings provide a mechanistic basis for GC resistance in T-ALL and highlight potential intervention points for restoring therapy sensitivity.

• Strategic Use of P2Y11 Antagonists in Cancer and Immunology

  2026-05-12

  This article explores the mechanistic and translational value of NF 340, a highly selective P2Y11 antagonist, in dissecting purinergic GPCR signaling in cancer and immune modulation. Building on the latest empirical evidence, including the reversal of breast cancer invasiveness via P2Y11 inhibition, it delivers practical protocol parameters, strategic insights for translational researchers, and a forward-thinking outlook on the future of GPCR-targeted research tools.

• Bay 11-7821 in Sepsis & Inflammatory Research: Mechanisms an

  2026-05-11

  Explore how Bay 11-7821 (BAY 11-7082) advances inflammatory signaling pathway research, uniquely bridging NF-κB inhibition with emerging insights from lactate-driven macrophage biology. Detailed protocols and critical assay considerations set this article apart.

• Oligomycin A in Translational Oncology: Mitochondrial Contro

  2026-05-11

  This thought-leadership article dissects the mechanistic power of Oligomycin A as a mitochondrial ATP synthase inhibitor to illuminate new strategies for translational cancer research. By integrating recent immunometabolic findings and comparative workflow guidance, it provides actionable protocols and a vision for the next wave of metabolic intervention in oncology.

• Tunicamycin as a Translational Lever: Mechanism, Strategy, a

  2026-05-10

  This thought-leadership article explores how Tunicamycin, a benchmark N-glycosylation inhibitor, enables translational researchers to dissect endoplasmic reticulum (ER) stress, immune regulation, and inflammation suppression with unprecedented mechanistic clarity. By contextualizing recent evidence and competitive insights, we provide strategic guidance for leveraging Tunicamycin in advanced translational workflows, and highlight both the promise and boundaries of its application.

• Nonivamide: Capsaicin Analog for Advanced TRPV1 Cancer Model

  2026-05-09

  Nonivamide, a next-generation capsaicin analog, empowers researchers with precise control over TRPV1-driven apoptosis and cancer cell growth inhibition. Its robust solubility profile and validated efficacy in both in vitro and in vivo oncology models set it apart as a cornerstone tool for translational cancer and neuroimmune research.

• Tofacitinib Citrate (CP-690550 Citrate) in Immune Regulation

  2026-05-08

  Tofacitinib citrate (CP-690550 citrate) empowers immune regulation and inflammatory disorder research through highly selective JAK3 inhibition. This guide details advanced experimental workflows, protocol enhancements, and troubleshooting strategies, leveraging new insights into vascular and cytokine-driven endothelial responses.

• Intestinal TM6SF2 Safeguards Against MASH via the Gut–Liver

  2026-05-08

  This study uncovers the protective role of intestinal TM6SF2 against metabolic dysfunction-associated steatohepatitis (MASH) by regulating gut barrier function and microbiota composition. The findings reveal a mechanistic link between gut-derived lipid signaling and hepatic inflammation, suggesting new intervention strategies.

• Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis A

  2026-05-07

  Anlotinib hydrochloride enables precise, highly potent inhibition of tumor angiogenesis by targeting VEGFR2, PDGFRβ, and FGFR1. Its superior activity streamlines endothelial migration and tube formation assays, providing cancer researchers a robust, reproducible platform for anti-angiogenic drug discovery.

• Revisiting Sumatriptan Metabolism: CYP and MAO Pathway Insig

  2026-05-07

  This study challenges the prevailing view that sumatriptan is metabolized exclusively by MAO A, presenting evidence that cytochrome P450 enzymes (CYP1A2, CYP2C19, CYP2D6) also play a significant role. These findings refine our understanding of drug metabolism pathways and have implications for neuropharmacology and drug interaction studies.

• Metronidazole in Research: OAT3 Inhibition & Microbiome Modu

  2026-05-06

  Metronidazole offers researchers a dual-action tool, uniquely bridging antimicrobial activity and selective inhibition of organic anion transporters. This article provides stepwise experimental guidance, troubleshooting insights, and protocol precision for leveraging Metronidazole in both microbiota-immunity and drug-drug interaction studies.

14961 records 1/998 page Next 12345 下5页 Last page